GLP-1 and Ozempic are not the same thing, but they’re closely related. GLP-1 is a hormone your body produces naturally, while Ozempic is a prescription medication designed to mimic that hormone. Think of it this way: GLP-1 is the biological original, and Ozempic is a lab-made version engineered to last much longer in your body.
What GLP-1 Actually Is
GLP-1, short for glucagon-like peptide-1, is a hormone made by your small intestine. When you eat, your gut releases GLP-1 to help manage blood sugar. It does this by signaling your pancreas to produce more insulin, telling your liver to slow down sugar production, and slowing digestion so food moves through your stomach more gradually. It also communicates with your brain to reduce appetite. The natural hormone breaks down in your body within minutes, which is why it works as a brief, meal-triggered signal rather than a long-lasting one.
How Ozempic Relates to GLP-1
Ozempic’s active ingredient is semaglutide, a manufactured molecule that attaches to the same receptors as natural GLP-1 and triggers the same effects. The key difference is durability. While your body’s own GLP-1 disappears in minutes, semaglutide has been structurally modified to resist breakdown, which is why Ozempic only needs to be injected once a week. It belongs to a class of drugs called GLP-1 receptor agonists, a term that simply means “substances that activate the GLP-1 receptor.”
So when people casually refer to Ozempic as “a GLP-1,” they’re using shorthand for “a GLP-1 receptor agonist.” It’s not the hormone itself. It’s a drug that impersonates the hormone.
Other Drugs in the GLP-1 Class
Ozempic isn’t the only GLP-1 receptor agonist on the market. Several medications use the same basic approach of mimicking GLP-1, though they differ in their active ingredients, dosing schedules, and approved uses. One that causes particular confusion is Wegovy, which contains the exact same active ingredient as Ozempic (semaglutide) but is FDA-approved specifically for weight management rather than diabetes. Wegovy also comes in a higher maximum dose of 2.4 mg per week, compared to Ozempic’s maximum of 2 mg.
Other GLP-1 receptor agonists use different molecules entirely, such as liraglutide or dulaglutide. They all work on the same receptor, but they vary in how long they last, how they’re taken, and what conditions they’re approved to treat.
What Ozempic Is Approved to Treat
The FDA has approved Ozempic for three uses, all tied to type 2 diabetes. It can be used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. It’s also approved to reduce the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes and existing heart disease. More recently, it gained approval to protect kidney function in adults with type 2 diabetes and chronic kidney disease.
Notably, Ozempic is not FDA-approved for weight loss on its own. That distinction belongs to Wegovy. Many people do lose weight on Ozempic, and some doctors prescribe it off-label for that purpose, but the drug’s formal indications are all diabetes-related.
How the Dosing Works
Ozempic is a once-weekly injection given under the skin, typically in the stomach, thigh, or upper arm. The dose starts low and increases gradually to reduce side effects. You begin at 0.25 mg per week for the first four weeks, which is considered a starter dose rather than a treatment dose. At week five, the dose increases to 0.5 mg. From there, your doctor may raise it further based on how your blood sugar responds and how well you tolerate the medication. The maximum dose is 2 mg per week.
Common Side Effects
Because GLP-1 receptor agonists slow digestion and affect gut signaling, the most common side effects are gastrointestinal. Nausea is the biggest one, affecting roughly 15% to 20% of people taking Ozempic. Diarrhea occurs in about 8%, stomach pain in 6% to 7%, vomiting in 5% to 9%, and constipation in 3% to 7%. These side effects tend to be worst during the dose-increase phase and often improve over time as your body adjusts.
Low blood sugar is relatively uncommon when Ozempic is used alone, occurring in fewer than 4% of patients in clinical studies. But when combined with insulin or certain other diabetes medications, the rate climbs significantly, reaching up to about 30% in some trial groups.
Safety Concerns to Know About
Ozempic carries a boxed warning, the FDA’s most serious label alert, regarding thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors at doses relevant to humans. Whether this translates to a risk in people remains unknown, but the drug is not appropriate for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Pancreatitis is another concern. In clinical trials, acute pancreatitis occurred in about 0.3% of Ozempic-treated patients per year, compared to 0.2% in comparison groups. There have also been post-marketing reports of acute kidney injury, primarily in patients experiencing severe nausea, vomiting, or dehydration from the medication. People with existing eye complications from diabetes should be monitored as well: diabetic retinopathy complications occurred in 3% of Ozempic patients in a two-year trial versus 1.8% on placebo.
The Bottom Line on GLP-1 vs. Ozempic
GLP-1 is a category. Ozempic is one product within that category. Your body makes GLP-1 naturally every time you eat. Ozempic delivers a longer-lasting synthetic version of it through a weekly injection. When someone says they’re “on GLP-1,” they almost always mean they’re taking a GLP-1 receptor agonist like Ozempic, not that they’re supplementing the raw hormone. The distinction matters because there are multiple drugs in this class with different approved uses, doses, and price points, and not all of them are interchangeable.